Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway

Background: Lcz696 (ARNI, angiotensin receptor–neprilysin inhibitor; sacubitril/valsartan) shows an inhibitory effect on fibrosis after myocardial infarction (MI). However, the underlying signaling mechanisms are poorly understood. The Wnt/β-catenin signaling pathway is activated after MI and partic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Zheng, Xuehui, Zhang, Chen, Zhang, Chunmei, Bu, Peili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443774/
https://www.ncbi.nlm.nih.gov/pubmed/34539406
http://dx.doi.org/10.3389/fphar.2021.724147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443774/
https://www.ncbi.nlm.nih.gov/pubmed/34539406
http://dx.doi.org/10.3389/fphar.2021.724147

Ejemplares similares